Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project
Impact of Cystatin-C C-guided Vancomycin Dosing Recommendation on Target Trough Achievement and Clinical Outcomes in Critically Ill Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Hospitalized in one of three intensive care units at Mayo Clinic in Rochester, Minnesota
- Suspected or documented gram-positive infection
- Prescribed IV vancomycin at a consistent dose and scheduled with 8, 12, or 24 hour Vancomycin dosing interval
Exclusion Criteria:
- Vulnerable population
- Received greater than 1 dose of Vancomycin in the 96 hours before ICU admission
- Baseline glomerular filtration rate (GFR) of less than 20 milliliters/minute
- Undergoing renal replacement therapy
- Body mass index > 40kg/m2
- Weight < 40kg
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cystatin C-guided vancomycin dosing algorithm
Cystatin C is an endogenous cysteine proteinase inhibitor produced by all nucleated cells and a biomarker used routinely to estimate glomerular filtration rate either alone or in combination with creatinine.
This new dosing algorithm includes patient weight, individualized goal trough concentration, and glomerular filtration rate (expressed with the CKD-EPI creatinine-cystatin C equation in mL/min) to determine dose and frequency.
|
Intravenous
Other Names:
Expressed in milliliters per minute
|
|
Other: Creatinine clearance guided vancomycin dosing
Historical controls for the quality improvement project had doses based on weight and interval established with the creatinine clearance using the Cockcroft-Gault equation.
|
Intravenous
Other Names:
Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vancomycin target trough achievement
Time Frame: Baseline
|
The percentage of initial steady state troughs within the target range.
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of stay (hospital and ICU)
Time Frame: Baseline
|
Baseline
|
|
|
Acute kidney injury (AKI) and renal replacement therapy
Time Frame: 7-days
|
New onset AKI, defined as KDIGO stage II or greater AKI, within 48-hours of and within 7-days of vancomycin initiation
|
7-days
|
|
Treatment failure
Time Frame: 7-days
|
Treatment failure in patients with confirmed gram-positive infection after at least 48-hours of vancomycin therapy and within 7-days
|
7-days
|
|
Infection recurrence
Time Frame: 28-days
|
New onset of infection within 28-days among patients with confirmed gram-positive infection
|
28-days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Erin Frazee, PharmD, RPh, Mayo Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14-002808
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.